Drug Profile
Oxycodone controlled-release - Intellipharmaceutics
Alternative Names: Abuse deterrent oxycodone hydrochloride extended release tablets - Intellipharmaceutics; Abuse-resistant oxycodone - Intellipharmaceutics; Aximris XR; Oxycodone CR - Intellipharmaceutics; Oxycodone ER - Intellipharmaceutics; Oxycodone hydrochloride extended-release tablets - Intellipharmaceutics; Rexista oxycodoneLatest Information Update: 08 Jan 2022
Price :
$50
*
At a glance
- Originator Intellipharmaceutics International
- Class Alkaloids; Morphine derivatives; Opioid analgesics; Small molecules
- Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Pain
Most Recent Events
- 02 Jul 2020 Intellipharmaceutics and Purdue Pharmaceuticals enter into a stipulated dismissal agreement to terminate the patent litigation in respect to NDA filing in USA
- 28 May 2020 No recent reports of development identified for phase-I development in Pain(In volunteers) in Canada (PO, Tablet)
- 16 Jan 2020 The Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the US FDA voted to not support the approval of oxycodone extended-release tablets for pain